Company intelligence / Profile preview
FivepHusion
New South Wales, Australiafivephusion.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Deflexifol™ is in advanced clinical stage development, with a global phase III registration trial planned to start in metastatic colorectal cancer in late 2024. The company has also secured an exclusive option over the ResectAssist™ Drug Delivery Platform.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculesdrug reformulations
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
University of WollongongAllarity TherapeuticsTreehill PartnersSyneos Health
Beyond the preview
Go deeper on FivepHusion.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FivepHusion.